Axonics Modulation Technologies Inc (AXNX)

$66.55

-0.09

(-0.14%)▲

Live

Insights on Axonics Modulation Technologies Inc

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 22.70M → 109.73M (in $), with an average increase of 45.4% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 4 quarters, -9.24M → 6.57M (in $), with an average increase of 117.7% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 42.7% return, outperforming this stock by 28.1%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 70.6% return, outperforming this stock by 63.0%

Performance

  • $66.52
    $66.75
    $66.55
    downward going graph

    0.05%

    Downside

    Day's Volatility :0.34%

    Upside

    0.3%

    downward going graph
  • $47.59
    $69.68
    $66.55
    downward going graph

    28.49%

    Downside

    52 Weeks Volatility :31.7%

    Upside

    4.49%

    downward going graph

Returns

PeriodAxonics Modulation Technologies IncSector (Health Care)Index (Russel 2000)
3 Months
-2.36%
1.7%
0.0%
6 Months
31.1%
11.3%
0.0%
1 Year
14.62%
5.4%
1.3%
3 Years
6.4%
13.9%
-22.1%

Highlights

Market Capitalization
3.4B
Book Value
$12.56
Earnings Per Share (EPS)
-0.12
Wall Street Target Price
71.73
Profit Margin
-1.66%
Operating Margin TTM
3.93%
Return On Assets TTM
-0.43%
Return On Equity TTM
-1.01%
Revenue TTM
366.4M
Revenue Per Share TTM
7.47
Quarterly Revenue Growth YOY
27.700000000000003%
Gross Profit TTM
197.7M
EBITDA
7.8M
Diluted Eps TTM
-0.12
Quarterly Earnings Growth YOY
8.45
EPS Estimate Current Year
0.45
EPS Estimate Next Year
0.84
EPS Estimate Current Quarter
0.06
EPS Estimate Next Quarter
-0.09

Analyst Recommendation

Buy
    90%Buy
    9%Hold
    0
    0%Sell
Based on 21 Wall street analysts offering stock ratings for Axonics Modulation Technologies Inc(by analysts ranked 0 to 5 stars)
Based on 21 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
19
17
18
Hold
2
3
3
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 7.78%

Current $66.55
Target $71.73

Company Financials

FY18Y/Y Change
Revenue
707.0K
↑ 451.84%
Net Income
-32.5M
↑ 79.85%
Net Profit Margin
-4.6K%
↑ 9502.57%
FY19Y/Y Change
Revenue
13.8M
↑ 1854.74%
Net Income
-79.9M
↑ 146.08%
Net Profit Margin
-578.4%
↑ 4016.08%
FY20Y/Y Change
Revenue
111.5M
↑ 707.05%
Net Income
-54.9M
↓ 31.3%
Net Profit Margin
-49.24%
↑ 529.16%
FY21Y/Y Change
Revenue
180.3M
↑ 61.64%
Net Income
-80.1M
↑ 45.8%
Net Profit Margin
-44.41%
↑ 4.83%
FY22Y/Y Change
Revenue
273.7M
↑ 51.81%
Net Income
-59.7M
↓ 25.44%
Net Profit Margin
-21.81%
↑ 22.6%
FY23Y/Y Change
Revenue
366.4M
↑ 33.86%
Net Income
-6.1M
↓ 89.8%
Net Profit Margin
-1.66%
↑ 20.15%
Q3 FY22Q/Q Change
Revenue
70.4M
↑ 2.04%
Net Income
-16.3M
↓ 24.21%
Net Profit Margin
-23.09%
↑ 8.0%
Q4 FY22Q/Q Change
Revenue
85.9M
↑ 22.07%
Net Income
665.0K
↓ 104.09%
Net Profit Margin
0.77%
↑ 23.86%
Q1 FY23Q/Q Change
Revenue
70.7M
↓ 17.77%
Net Income
-9.2M
↓ 1490.68%
Net Profit Margin
-13.09%
↓ 13.86%
Q2 FY23Q/Q Change
Revenue
22.7M
↓ 67.86%
Net Income
-7.3M
↓ 20.61%
Net Profit Margin
-32.34%
↓ 19.25%
Q3 FY23Q/Q Change
Revenue
93.1M
↑ 310.06%
Net Income
3.9M
↓ 153.5%
Net Profit Margin
4.22%
↑ 36.56%
Q4 FY23Q/Q Change
Revenue
109.7M
↑ 17.87%
Net Income
6.6M
↑ 67.36%
Net Profit Margin
5.99%
↑ 1.77%
FY18Y/Y Change
Total Assets
171.9M
↑ 484.48%
Total Liabilities
28.6M
↓ 55.79%
FY19Y/Y Change
Total Assets
219.8M
↑ 27.87%
Total Liabilities
36.8M
↑ 28.6%
FY20Y/Y Change
Total Assets
342.2M
↑ 55.67%
Total Liabilities
54.8M
↑ 48.93%
FY21Y/Y Change
Total Assets
547.9M
↑ 60.12%
Total Liabilities
65.5M
↑ 19.46%
FY22Y/Y Change
Total Assets
659.4M
↑ 20.33%
Total Liabilities
89.2M
↑ 36.19%
FY23Y/Y Change
Total Assets
719.9M
↑ 9.19%
Total Liabilities
82.4M
↓ 7.68%
Q3 FY22Q/Q Change
Total Assets
632.3M
↑ 22.99%
Total Liabilities
82.8M
↑ 8.38%
Q4 FY22Q/Q Change
Total Assets
659.4M
↑ 4.28%
Total Liabilities
89.2M
↑ 7.8%
Q1 FY23Q/Q Change
Total Assets
665.7M
↑ 0.96%
Total Liabilities
89.1M
↓ 0.14%
Q2 FY23Q/Q Change
Total Assets
649.0M
↓ 2.51%
Total Liabilities
33.3M
↓ 62.64%
Q3 FY23Q/Q Change
Total Assets
660.7M
↑ 1.81%
Total Liabilities
50.1M
↑ 50.61%
Q4 FY23Q/Q Change
Total Assets
719.9M
↑ 8.96%
Total Liabilities
82.4M
↑ 64.3%
FY18Y/Y Change
Operating Cash Flow
-31.4M
↑ 72.61%
Investing Cash Flow
-60.1M
↑ 5679.6%
Financing Cash Flow
165.3M
↑ 374.93%
FY19Y/Y Change
Operating Cash Flow
-83.5M
↑ 166.03%
Investing Cash Flow
45.3M
↓ 175.42%
Financing Cash Flow
111.0M
↓ 32.89%
FY20Y/Y Change
Operating Cash Flow
-83.7M
↑ 0.35%
Investing Cash Flow
9.7M
↓ 78.68%
Financing Cash Flow
144.2M
↑ 29.95%
FY21Y/Y Change
Operating Cash Flow
-47.3M
↓ 43.51%
Investing Cash Flow
-143.0M
↓ 1581.27%
Financing Cash Flow
170.5M
↑ 18.26%
FY22Y/Y Change
Operating Cash Flow
3.2M
↓ 106.75%
Investing Cash Flow
-120.4M
↓ 15.84%
Financing Cash Flow
134.0M
↓ 21.43%
Q3 FY22Q/Q Change
Operating Cash Flow
3.8M
↓ 556.89%
Investing Cash Flow
-99.4M
↑ 834.92%
Financing Cash Flow
131.9M
↑ 27375.63%
Q4 FY22Q/Q Change
Operating Cash Flow
9.4M
↑ 143.12%
Investing Cash Flow
-10.0M
↓ 89.91%
Financing Cash Flow
161.0K
↓ 99.88%
Q1 FY23Q/Q Change
Operating Cash Flow
-781.0K
↓ 108.35%
Investing Cash Flow
694.0K
↓ 106.92%
Financing Cash Flow
1.9M
↑ 1098.76%
Q2 FY23Q/Q Change
Operating Cash Flow
-19.2M
↑ 2359.54%
Investing Cash Flow
-11.1M
↓ 1692.65%
Financing Cash Flow
-6.8M
↓ 450.57%
Q3 FY23Q/Q Change
Operating Cash Flow
12.3M
↓ 164.26%
Investing Cash Flow
-11.1M
↑ 0.0%
Financing Cash Flow
878.0K
↓ 112.98%

Technicals Summary

Sell

Neutral

Buy

Axonics Modulation Technologies Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Axonics Modulation Technologies Inc
Axonics Modulation Technologies Inc
-3.04%
31.1%
14.62%
6.4%
228.44%
Stryker Corporation
Stryker Corporation
-4.04%
30.03%
12.47%
26.98%
79.97%
Dexcom, Inc.
Dexcom, Inc.
-1.59%
63.45%
11.22%
31.69%
366.88%
Boston Scientific Corp.
Boston Scientific Corp.
8.35%
45.85%
42.65%
72.49%
97.43%
Abbott Laboratories
Abbott Laboratories
-2.84%
14.24%
-2.8%
-12.8%
36.85%
Medtronic Plc
Medtronic Plc
-3.44%
12.58%
-10.38%
-38.23%
-7.46%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Axonics Modulation Technologies Inc
Axonics Modulation Technologies Inc
NA
NA
NA
0.45
-0.01
0.0
NA
12.56
Stryker Corporation
Stryker Corporation
40.64
40.64
2.92
11.85
0.18
0.07
0.01
48.92
Dexcom, Inc.
Dexcom, Inc.
102.89
102.89
2.53
1.76
0.26
0.06
NA
5.37
Boston Scientific Corp.
Boston Scientific Corp.
64.48
64.48
1.8
2.25
0.09
0.04
NA
13.16
Abbott Laboratories
Abbott Laboratories
33.52
33.52
5.99
4.31
0.15
0.06
0.02
22.26
Medtronic Plc
Medtronic Plc
25.81
25.81
1.52
5.2
0.08
0.04
0.03
38.95
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Axonics Modulation Technologies Inc
Axonics Modulation Technologies Inc
Buy
$3.4B
228.44%
NA
-1.66%
Stryker Corporation
Stryker Corporation
Buy
$127.4B
79.97%
40.64
15.44%
Dexcom, Inc.
Dexcom, Inc.
Buy
$54.6B
366.88%
102.89
14.95%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$101.4B
97.43%
64.48
11.18%
Abbott Laboratories
Abbott Laboratories
Buy
$186.7B
36.85%
33.52
13.96%
Medtronic Plc
Medtronic Plc
Buy
$107.9B
-7.46%
25.81
13.0%

Institutional Holdings

  • FMR Inc

    10.64%

  • Vanguard Group Inc

    10.31%

  • BlackRock Inc

    8.21%

  • Champlain Investment Partners, LLC

    3.76%

  • Bellevue Group AG

    3.59%

  • Amvescap Plc.

    3.58%

Corporate Announcements

  • Axonics Modulation Technologies Inc Earnings

    Axonics Modulation Technologies Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

axonics modulation technologies, inc is a privately-held medical device company developing an innovative neuromodulation platform based on a miniaturized rechargeable fully-implantable ipg licensed from the alfred mann foundation. the axonics sacral neuromodulation system is designed to improve the experience of both clinicians and patients suffering from urinary and fecal dysfunction.

Organization
Axonics Modulation Technologies Inc
Employees
797
CEO
Mr. Raymond W. Cohen
Industry
Health Technology

Discover More

FAQs